Enanta Pharmaceuticals appeal oral argument set for May 11, 2026; litigation targets Pfizer over Paxlovid patent infringement
Reuters
Mar 26
Enanta Pharmaceuticals appeal oral argument set for May 11, 2026; litigation targets Pfizer over Paxlovid patent infringement
Enanta is appealing a Federal Circuit case against Pfizer seeking damages for alleged infringement of U.S. Patent No. 11,358,953 related to Paxlovid.
Oral argument in the appeal is scheduled for May 11, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-125113), on March 26, 2026, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.